Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic lupus erythematosus
•
Pediatric Rheumatology
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?
Related Questions
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
Are there instances in which you would combine belimumab and rituximab for management of difficult to control SLE?
In a patient with SJIA who has been stable on Anakinra however is now planning to conceive or becomes pregnant, would you consider switching to Cimzia?
Do you check mycophenolate levels in patients prescribed mycophenolate who present with a lupus nephritis flare?
Would you be comfortable combining rituximab with voclosporin in patients with lupus nephritis not responding to standard therapy?
How do you approach the initial treatment for a patient presenting with MAS/HLH as the initial manifestation of SLE?
How do you counsel a patient with SLE who has labs suggesting active non-renal disease on the benefits of escalation of treatment if they aren't experiencing noticeable symptoms?
How would you manage a patient SLE who is planning pregnancy and has serologically active disease (elevated dsDNA, low C3/C4), mild arthritis, and is otherwise asymptomatic on hydroxychloroquine 200 mg BID and methotrexate 15 mg weekly?
Do you always pursue testing for NOD2 mutations when you are suspecting a diagnosis of Blau syndrome?
How would you approach management of a patient with sJIA that was previously well controlled on tocilizumab but is now having ongoing joint disease activity?
